Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis

OBJECTIVE: Cemiplimab combined with chemotherapy has emerged as a promising treatment option for advanced non-small cell lung cancer (NSCLC). Accordingly, this study has been conducted to evaluate the cost-effectiveness of this combination therapy in comparison to chemotherapy alone from the perspec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Gaofeng, Cai, Hongfu, Zheng, Zhiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666692/
https://www.ncbi.nlm.nih.gov/pubmed/38028144
http://dx.doi.org/10.1177/17588359231213619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666692/
https://www.ncbi.nlm.nih.gov/pubmed/38028144
http://dx.doi.org/10.1177/17588359231213619

Ejemplares similares